Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 6, 2010, Pages

  Lucas, Mary ^a,d   Lee, Martin ^c   Lortan, Jenny ^b,d   Lopez Granados, Eduardo ^a,d   Misbah, Siraj ^a,d   Chapel, Helen ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

clinical phenotypes; complications; CVIDs; infection outcome; Long term follow up

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BRONCHIECTASIS; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPOTHESIS; IMMUNOTHERAPY; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INFECTION; X LINKED AGAMMAGLOBULINEMIA;

EID: 77952741985     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.02.040     Document Type: Article

References (32)

1. Geha R.S., Notarangelo L.D., Casanova J.L., Chapel H., Conley M.E., Fischer A., et al. International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 120 (2007) 776-794
2. Wood P. Primary antibody deficiency syndromes. Ann Clin Biochem 46 (2009) 99-108
3. Chapel H., Lucas M., Lee M., Bjorkander J., Webster D., Grimbacher B., et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 112 (2008) 277-286
4. Busse P.J., Razvi S., and Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109 (2002) 1001-1004
5. de Gracia J., Vendrell M., Alvarez A., Pallisa E., Rodrigo M.J., de la Rosa D., et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 4 (2004) 745-753
6. Skull S., and Kemp A. Treatment of hypogammaglobulinaemia with IVIg 1973-1993. Arch Dis Child 74 (1996) 527-530
7. De Santis W., Esposito A., Conti V., Fantauzzi A., Guerra A., Mezzaroma I., et al. [Health care and infective aspects in patients affected by common variable immunodeficiency assisted in the Lazio Regional Authority Reference Centre for Primary Immunodeficiencies]. Infez Med 14 (2006) 13-23
8. Pourpak Z., Aghamohammadi A., Sedighipour L., Farhoudi A., Movahedi M., Gharagozlou M., et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J Microbiol Immunol Infect 39 (2006) 114-120
9. Favre O., Leimgruber A., Nicole A., and Spertini F. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy 60 (2005) 385-390
10. Martinez Garcia M.A., de Rojas M.D., Nauffal Manzur M.D., Munoz Pamplona M.P., Compte Torrero L., Macian V., et al. Respiratory disorders in common variable immunodeficiency. Respir Med 95 (2001) 191-195
11. Quinti I., Soresina A., Spadaro G., Martino S., Donnanno S., Agostini C., et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 27 (2007) 308-316
12. Cunningham-Rundles C., and Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92 (1999) 34-48
13. Bayrakci B., Ersoy F., Sanal O., Kilic S., Metin A., and Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr 47 (2005) 239-246
14. Leen C.L., Yap P.L., and McClelland D.B. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualization of intravenous immunoglobulin. Vox Sang 51 (1986) 278-286
15. Bonagura V.R., Marchlewski R., Cox A., and Rosenthal D.W. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 122 (2008) 210-212
16. Montanaro A., and Pirofsky B. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states. Am J Med 76 (1984) 67-72
17. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia: a review. Am J Med 76 (1984) 53-60
18. Bernatowska E., Madalinski K., Janowicz W., Weremowicz R., Gutkowski P., Wolf H.M., et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 43 (1987) 153-162
19. Eijkhout H.W., Van Der-Meer J.W., Kallenberg C.G., Weening R.S., van Dissel J.T., Sanders L.A., et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 135 (2001) 165-174
20. Roifman C.M., Schroeder H., Berger M., Sorensen R., Ballow M., Buckley R.H., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 3 (2003) 1325-1333
21. Roifman C., Levison H., and Gelfand E.W. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1 (1987) 1075-1077
22. Pruzanski W., Sussman G., Dorian W., Van T., Ibanez D., and Redelmeier D. Relationship of the dose of IVIg to the prevention of infections in adults with CVIDs. Inflammation 20 (1996) 353-359
23. Sorensen R.U., and Polmar S.H. Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes. Am J Med 76 (1984) 83-90
24. Ochs H.D., Fischer S.H., Wedgwood R.J., Wara D.W., Cowan M.J., Ammann A.J., et al. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 76 (1984) 78-82
25. Pettit S.J., Bourne H., and Spickett G.P. Survey of infection in patients receiving antibody replacement treatment for immune deficiency. J Clin Pathol 55 (2002) 577-580
26. Tang M. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency. 1st ed, November 2008. Available at: http://www.apiieg.org/STATEMENTS.ASP. Accessed June 29, 2009.
27. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553
28. Shehata N., Hume H., Palda V., Anderson D., Bowen T., Warrington R., et al. Immune globulin for patients with primary immune deficiency: an evidence based practice guideline. Tranfus Med Rev 24 suppl 1 (2010) 7-27
29. Chapel H.M., and Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. Consensus on diagnosis and management of primary antibody deficiencies. Br Med J 308 (1994) 581-585
30. Conley M.E., Notarangelo L.D., and Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 93 (1999) 190-197
31. Ward C., Lucas M., Piris J., Collier J., and Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol 153 (2008) 331-337
32. ED Mixed Models-theory and applications (2004), John Wiley and Sons, Hoboken (NJ)